Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings Call Transcripts
Arrowhead Pharmaceuticals, Inc.'s Latest Earnings Call - June 10, 2026
Arrowhead Pharmaceuticals' Q2 2026 earnings call highlighted significant developments, particularly in their cardiometabolic and CNS portfolios. The company reported strong progress in transitioning from R&D to a commercial organization, focusing on the upcoming Phase III readouts for their drug plozasiran, marketed as Redemplo. Revenue and earnings specifics were not disclosed, but the company emphasized expanding their commercial footprint due to promising early results. Management provided no explicit guidance changes but indicated a focus on commercial execution and upcoming clinical data releases.
Reported metrics
| Metric | Value |
|---|---|
| Market Opportunity for FCS | Well north of 6,000 patients (positive) |
| Switch Rate from Competitors | Over 10% (positive) |
| European Approval Timing | Expected this month (positive) |
| Pricing Adjustment | $45,000 WAC (neutral) |
Guidance from management
Management did not provide specific forward guidance but emphasized a focus on commercial execution and the importance of upcoming clinical data releases.
What management said
Yes. So we won't give out too many details about that. It's kind of proprietary. We do have sort of the classical physician ID where we look at physicians who are treating FCS-like characteristics. And so that's a pretty easy way to determine some targeting there. We also have some consumer-based marketing to go out and identify these patients. It is very, very much an underdiagnosed condition. And then we do have a ...
Yes. So I think the biggest challenge is around identifying them and then ensuring that the physicians are completely familiar with the therapies that are available. In terms of physician preference, I think,they will -- they would naturally prefer a molecule that is more effective, that is more convenient for you. But both are actually, at the end of the day, very effective tools. And so it's really identifying the ...
What analysts pressed on
Analysts expressed concerns about the potential for numerical but not statistically significant results in the SHASTA-3 and -4 studies, questioning the impact on prescriber behavior and the necessity of SHASTA-5. There were also questions about pricing strategy and market penetration in light of competitor actions.
Main topics on the call
- Commercial Expansion — Arrowhead is expanding its commercial footprint due to promising early results in the FCS market, indicating a larger market opportunity than initially expected. Management stated, 'we have made the decision to start to ...
- Phase III Readouts — The upcoming Phase III readouts for SHASTA-3 and -4 studies are pivotal, with expectations of significant triglyceride reduction and potential acute pancreatitis risk reduction. Management emphasized the importance of th...
- European Market Expansion — Arrowhead expects EMA approval for Redemplo, which would make it the only provider in Europe with clinical FCS under its label. This could enhance market penetration, as stated, 'we are hopeful to get that actually this ...
- Pricing Strategy — Arrowhead recently adjusted the price of Redemplo to $45,000, aligning with payer expectations and removing uncertainty. Management noted, 'we recently repriced down to the WAC of $45,000... it removed uncertainty.'
Read the full Arrowhead Pharmaceuticals, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 71 calls on record spanning February 5, 2020 to August 4, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 71 Arrowhead Pharmaceuticals, Inc. earnings call transcripts on record, spanning February 5, 2020 to August 4, 2026. Based on this history, Arrowhead Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ARWR
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 71
- First call
- February 5, 2020
- Most recent
- August 4, 2026
- Reporting cadence
- quarterly